Evidence map›Paper›PMID 24523933›Full record

ArticlePloS one2014

Fcγ receptor-mediated inflammation inhibits axon regeneration.

Gang Zhang, Nataliia Bogdanova, Tong Gao, Julia J Song, Mark S Cragg, Martin J Glennie, Kazim A Sheikh

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Role of Fcγ Receptor Mediated Inflammation in Immune Neuropathies.Journal of clinical & cellular immunology · 2017
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Anti-Ganglioside Antibodies Induce Nodal and Axonal Injury via Fcγ Receptor-Mediated Inflammation.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Gang ZhangDepartment of Neurology, University of Texas Medical School at Houston, Houston, Texas, United States of America.
Nataliia BogdanovaDepartment of Neurology, University of Texas Medical School at Houston, Houston, Texas, United States of America.
Tong GaoDepartment of Neurology, University of Texas Medical School at Houston, Houston, Texas, United States of America.
Julia J SongDepartment of Neurology, University of Texas Medical School at Houston, Houston, Texas, United States of America.
Mark S CraggAntibody and Vaccine Group, Cancer Sciences Division, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Martin J GlennieAntibody and Vaccine Group, Cancer Sciences Division, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Kazim A SheikhDepartment of Neurology, University of Texas Medical School at Houston, Houston, Texas, United States of America.
University of Southampton · GB

Funding

Pathogenesis of Anti-ganglioside Antibody-Mediated NeuropathiesR01NS042888 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SHEIKH, KAZIM A · 2002 to 2016
$4.1M
Biologic effects of anti-ganglisiode antibodiesR01NS054962 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SHEIKH, KAZIM A · 2007 to 2018
$3.3M
NINDS NIH HHS R01 NS042888NINDS NIH HHS R01 NS054962NINDS NIH HHS R01 NS42888NINDS NIH HHS R01 NS54962
6 · The paper itself

Abstract

Anti-glycan/ganglioside antibodies are the most common immune effectors found in patients with Guillain-Barré Syndrome, which is a peripheral autoimmune neuropathy. We previously reported that disease-relevant anti-glycan autoantibodies inhibited axon regeneration, which echo the clinical association of these antibodies and poor recovery in Guillain-Barré Syndrome. However, the specific molecular and cellular elements involved in this antibody-mediated inhibition of axon regeneration are not previously defined. This study examined the role of Fcγ receptors and macrophages in the antibody-mediated inhibition of axon regeneration. A well characterized antibody passive transfer sciatic nerve crush and transplant models were used to study the anti-ganglioside antibody-mediated inhibition of axon regeneration in wild type and various mutant and transgenic mice with altered expression of specific Fcγ receptors and macrophage/microglia populations. Outcome measures included behavior, electrophysiology, morphometry, immunocytochemistry, quantitative real-time PCR, and western blotting. We demonstrate that the presence of autoantibodies, directed against neuronal/axonal cell surface gangliosides, in the injured mammalian peripheral nerves switch the proregenerative inflammatory environment to growth inhibitory milieu by engaging specific activating Fcγ receptors on recruited monocyte-derived macrophages to cause severe inhibition of axon regeneration. Our data demonstrate that the antibody orchestrated Fcγ receptor-mediated switch in inflammation is one mechanism underlying inhibition of axon regeneration. These findings have clinical implications for nerve repair and recovery in antibody-mediated immune neuropathies. Our results add to the complexity of axon regeneration in injured peripheral and central nervous systems as adverse effects of B cells and autoantibodies on neural injury and repair are increasingly recognized.

Indexed as

Nerve RegenerationAnimalsAutoantibodiesAxonsBehavior, AnimalComplement ActivationDisease Models, AnimalGangliosidesGuillain-Barre SyndromeInflammationMacrophagesMaleMiceMice, TransgenicMutationPeripheral NervesAutoantibodiesFcgr4 protein, mouseGangliosidesReceptors, IgG

Identifiers

PMID24523933
PMCPMC3921223
OpenAlexW2007744660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.